Byoung-Shik Shim

Byoung-Shik Shim

Auto-generated profile, based on publicly available information

Byoung-Shik Shim

International Vaccine Institute, Seoul, Republic of Korea.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPuna Maya Maharjan
Puna Maya Maharjan
JCJinyeong Cheon
Jinyeong Cheon
JJJiyun Jung
Jiyun Jung
HKHaerim Kim
Haerim Kim
JLJaewon Lee
Jaewon Lee
SCSunghwa Choe
Sunghwa Choe
The current 15-month coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 has accounted for 3.77 million deaths and enormous worldwide social and economic losses. A high volume of vaccine production is urgently required to eliminate COVID-19. Inexpensive and robust production platforms will improve the distribution of vaccines to resource-limited countries. Plant species offer such platforms, particularly through the production of recombinant proteins to serve as immunogens. To achieve this goal, here we expressed the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein in the glycoengineered-tobacco plant Nicotiana benthamiana to provide a candidate subunit vaccine. This recombinant RBD elicited humoral immunity in mice via induction of highly neutralizing antibodies. These findings provide a strong foundation to further advance the development of plant-expressed RBD antigens for use as an effective, safe, and inexpensive SARS-CoV-2 vaccine. Moreover, our study further highlights the utility of plant species for vaccine development.

23 October 2025 in Journal of Virology
Verified
Journal Article
Open access
LZLizhou Zhang
Lizhou Zhang
BSByoung-Shik Shim
Byoung-Shik Shim
CKClaire Kitzmiller
Claire Kitzmiller
YKYoung-Chan Kwon
Young-Chan Kwon
ARAudrey Stéphanie Richard
Audrey Stéphanie Richard
HCHyeryun Choe
Hyeryun Choe
Many enveloped viruses engage phosphatidylserine (PS) receptors to enter cells, a phenomenon known as “apoptotic mimicry.” We previously reported that Zika virus (ZIKV), but not closely related West Nile virus (WNV) or dengue virus (DENV), utilized AXL to infect cells because only ZIKV could bind the AXL ligand GAS6, a PS-binding protein. In this study, we investigated the mechanisms underlying the differential ability of these viruses to bind GAS6. Although immature virions expose larger patches of the viral membrane than do mature ones, our data show that virion maturity levels did not contribute to GAS6 binding. Surprisingly, while ZIKV contains PS comparable to cellular membranes, PS on WNV and DENV is markedly reduced. These findings explain why only ZIKV can bind GAS6 and provide insights into a novel mechanism by which closely related flaviviruses differentially utilize cellular entry factors. IMPORTANCE: Among flaviviruses, Zika virus uniquely causes microcephaly and congenital defects. While no flavivirus-specific entry receptors have been identified, they commonly take advantage of phosphatidylserine (PS) receptors to enter cells. Our previous studies revealed that Zika virus uniquely utilizes AXL, found in immune-privileged sites, such as the brain and placenta, via binding to its ligand, GAS6. Our current study shows that despite being produced from the same cells, the Zika virus has substantially higher PS content than closely related dengue and West Nile viruses, which likely explains the Zika virus's unique ability to bind GAS6. These findings provide insight into how closely related flaviviruses can vary substantially in their use of cellular entry factors, potentially contributing to the distinct diseases they cause.

28 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKSoo Ji Kim
Soo Ji Kim
TKTaewoo Kim
Taewoo Kim
SBSatyanarayana Bejjani
Satyanarayana Bejjani
MKMi Sun Kim
Mi Sun Kim
JLJung Hyuk Lee
Jung Hyuk Lee
MSManki Song
Manki Song
Adjuvants play a crucial role in enhancing vaccine-induced immune responses by shaping the magnitude and quality of humoral and cellular immunity. However, the mechanism through which different adjuvants modulate effector functions is not fully understood. Here, we developed an International Vaccine Institute liposome-based adjuvant (ILA) and comprehensively compared humoral immune profiles in mice following the administration of SARS-CoV-2 spike (S) protein formulated with either ILA or aluminum hydroxide (alum) using a systems serology approach. No significant differences were observed in antigen-specific total IgG and neutralizing antibody titers between the two adjuvanted groups. However, the ILA group demonstrated a broader spectrum of humoral immune responses, exhibiting higher levels of antigen-specific IgG2a, IgG2b, and IgG3 compared to the alum group. In addition, S-specific antibody binding to Fcγ receptor (FcγR) 1 and FcγR4 was significantly higher in the ILA group compared to alum. Moreover, Fc-mediated effector functions, such as antibody-mediated monocyte and neutrophil phagocytosis, were significantly more active in the ILA-adjuvanted group. Overall, these findings demonstrate that ILA induces antibodies with superior FcγR binding and Fc-mediated effector functions compared to alum, highlighting its potential role in improving vaccine-induced immunity.

28 January 2025 in mSphere
Verified
Journal Article
Open access
JLJung Hyuk Lee
Jung Hyuk Lee
YSYuna Shin
Yuna Shin
KSKwang-Soo Shin
Kwang-Soo Shin
JPJu Yeon Park
Ju Yeon Park
MKMi Sun Kim
Mi Sun Kim
MSManki Song
Manki Song
AdCLD-CoV19-1, a chimeric adenovirus-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, was previously reported to elicit robust antibody responses in mice and non-human primates after a single dose. In this study, we conducted a systems serology analysis to investigate changes in humoral immune responses induced by varying doses of the AdCLD-CoV19-1 vaccine in a phase I clinical trial. Serum samples from participants receiving either a low or a high dose of the vaccine were analyzed for antibody features against prototype SARS-CoV-2 spike (S) domains (full-length S, S1, S2, and receptor binding domain), as well as Fc receptor binding and effector functions. While both low- and high-dose vaccines induced robust humoral immune responses following vaccination, the quality of antibody features differed between the dose groups. Notably, while no significant difference was observed between the groups in the induction of most S1-specific antibody features, the high-dose group exhibited higher levels of antibodies and a stronger Fc receptor binding response specific to the S2 antigen. Moreover, univariate and multivariate analyses revealed that the high-dose vaccine induced higher levels of S2-specific antibodies binding to FcγR2A and FcγR3B, closely associated with antibody-dependent neutrophil phagocytosis (ADNP). Further analysis using the Omicron BA.2 variant demonstrated that the high-dose group maintained significantly higher levels of IgG and FcγR3B binding to the S2 antigen and exhibited a significantly higher ADNP response for the S2 antigen compared with the low-dose group. These findings underscore the importance of considering diverse humoral immune responses when evaluating vaccine efficacy and provide insights for optimizing adenovirus vector-based SARS-CoV-2 vaccine doses. IMPORTANCE: Optimization of vaccine dose is crucial for eliciting effective immune responses. In addition to neutralizing antibodies, non-neutralizing antibodies that mediate Fc-dependent effector functions play a key role in protection against various infectious diseases, including coronavirus disease 2019. Using a systems serology approach, we demonstrated significant dose-dependent differences in the humoral immune responses induced by the AdCLD-CoV19-1 chimeric adenovirus-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, particularly against the SARS-CoV-2 spike 2 domain. These findings highlight the importance of assessing not only neutralizing antibody titers but also the quality and functionality of antibody responses when evaluating vaccine efficacy.

29 November 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
SJSeong-Mook Jung
Seong-Mook Jung
SKSoo Ji Kim
Soo Ji Kim
YPYoung Chae Park
Young Chae Park
ESEun Sang Seo
Eun Sang Seo
CKCheol Gyun Kim
Cheol Gyun Kim
YSYoung Min Son
Young Min Son
Background/Objectives: Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (TRM) cells and tissue-resident memory B (BRM) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses. However, the interactions between RSV vaccines and mucosal immune responses within the respiratory tract are poorly understood. We evaluated a mucosal immune system following immunization by RSV vaccine with poly-sorbitol transporter (RSV-PST), a nanoparticle adjuvant. Methods: We intranasally immunized the RSV-PST and identified the systemic and mucosal immune responses. Furthermore, we challenged with RSV A2 strain after immunization and investigated the protective effects. Results: Consequently, antigen-specific CD8+ TRM cells were markedly elevated in the lung parenchyma, yet exhibited impaired cytokine expression. In contrast, humoral immunity, with systemic antibody production from serum, but not in the respiratory tract, was significantly increased by RSV-PST immunization. Interestingly, the production of respiratory mucosal antigen-specific IgG after RSV A2 challenge dramatically increased in the bronchoalveolar lavage fluid (BALF) of the RSV-PST immunized group in the presence of FTY720, and the lung-infected RSV titer was significantly lower in this group. Furthermore, after RSV A2 challenge, CD69+ IgG+ BRM cells were significantly increased in lung tissues in the RSV-PST group. Conclusions: The RSV-PST vaccine has protective effects against RSV infection by promoting both systemic and local humoral immunity rather than cellular immunity.

28 March 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
MKMITSUTAKA KITANO
MITSUTAKA KITANO
BSByoung-Shik Shim
Byoung-Shik Shim
HSHitoshi Sasaki
Hitoshi Sasaki
JLJonathan Lovell
Jonathan Lovell
VKV. Narry Kim
V. Narry Kim
TETimothy Endy
Timothy Endy
On 9–10 December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) convened a workshop in Seoul under CEPI’s Disease X Program. The primary objective was to identify existing gaps needing to be filled and streamline vaccine development and preparedness for Severe Fever with Thrombocytopenia Syndrome (SFTS). CEPI’s partners and experts discussed a multifaceted agenda, ranging from understanding the evolving epidemiology to the refinement of animal models and immunological assay harmonization. Key outcomes included the refinement of Target Product Profiles (TPPs) specifying use cases for both peacetime and outbreak contexts, alongside a recommendation for a core immunoassay panel aimed at harmonizing evaluation frameworks and mitigating the challenges posed by low SFTS prevalence. Integration of the One Health approach emerged as a critical strategy for SFTS prevention, complemented by proactive regulatory engagement to compress vaccine development timelines. This report summarizes these key insights from the workshop, delineating a strategic framework for delivering safe, effective, and accessible vaccines for SFTS and broader Disease X threats.